Narrowing the Gap Between Diagnosis of Psoriasis and Psoriatic Arthritis
The causes for, and ways to improve, the diagnostic delays in patients with psoriasis who progress to psoriatic arthritis are discussed.
Psoriatic Arthritis
Effect of Tofacitinib on Quality of Life Mediated by Itch in Patients With Psoriatic Arthritis
The extent to which tofacitinib affects the health-related quality of life in patients with psoriatic arthritis was studied, based on improvements in itch.
Body Surface Area of Psoriasis Strongly Predicts Psoriatic Arthritis Risk
Researchers examined the association between psoriasis severity and the development of psoriatic arthritis.
Biologic Agents Reduce Psoriatic Arthritis Incidence
The effect of psoriasis treatment with biologic agents and incidence of psoriatic arthritis is examined.
Incidence of Psoriatic Arthritis Up With More Severe Psoriasis
Progression to psoriatic arthritis is common among patients with psoriasis, with increased incidence observed among patients with more severe disease.
Hospitalization Trends in Patients With Psoriasis
The longitudinal trends of psoriasis hospitalizations after the introduction of biologic agents is tracked.
Inflammatory Bowel Disease Risk in Patients With PsA and AS Initiating Treatment With IL-17 Inhibitors
Researchers assessed the association between initiation with IL-17 inhibitors and risk for inflammatory bowel disease in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
Ultrasound More Valuable Than Clinical Scores in Assessing Disease Activity in Patients With PsA With Concomitant Fibromyalgia
Researchers assessed the role of ultrasonography in the evaluation of disease activity in patients with psoriatic arthritis with concomitant fibromyalgia syndrome.
Increased Risk for Cardiovascular Disease in Patients With Concomitant Gout and Psoriasis
Using a population-based cohort, researchers assessed the effects of gout on risk for cardiovascular disease in patients with psoriasis.
Secukinumab vs Adalimumab in Concomitant PsA and Plaque Psoriasis
Secukinumab vs adalimumab for treatment in patients with concomitant plaque psoriasis and active psoriatic arthritis during 52 weeks is reported.
- Loading...
Loading...
Next post in Psoriasis
Loading... 
Loading...